BioSig Technologies, Inc. (NASDAQ:BSGM) has announced that physicians at Mayo Clinic’s campus in Phoenix, Arizona have started using the company’s PURE EP System in patient cases treating cardiac arrhythmias.
The 30-day clinical evaluation of the PURE EP System is being conducted by the cardiac electrophysiologists Win-Kuang Shen, Hichan El Masry, Arturo Valverde, and Luis Scott.
“We are pleased to expand our installation to a new Mayo Clinic campus, an institution that played, and continues to play, a vital role in defining the clinical value of the PURE EP System. We are thankful to all our physician collaborators and EP fellows at Mayo Clinic and look forward to reporting on more clinical and commercial progress,” commented Kenneth L. Londoner, BioSig chairman and CEO in a statement.
READ: BioSig taps two regional directors to lead its commercial expansion across southeast and central regions of the US
Mayo Clinic cares for more than one million people a year, from all 50 states and nearly 140 countries and the institution has consistently ranked at or near the top of the ‘Best Hospitals Honor Roll’.
To date, more than 660 patient cases have been conducted with the PURE EP System by over 40 physicians across nine clinical sites, including Texas Cardiac Arrhythmia Institute at St. David’s Medical Center in Austin, Texas, Mayo Clinic’s campus in Jacksonville, Florida, Massachusets General Hospital in Boston, Massachusetts and University of Pennsylvania in Philadelphia, Pennsylvania.
BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals.
The company’s first product, PURE EP System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.
Contact the author at jon.hopkins@proactiveinvestors.com